Protagonist Therapeutics Inc (NASDAQ:PTGX)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $1.56, but opened at $4.69. Protagonist Therapeutics shares last traded at $7.60, with a volume of 451,232 shares traded.
A number of equities research analysts recently weighed in on PTGX shares. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Nomura reissued a “buy” rating and issued a $29.00 target price on shares of Protagonist Therapeutics in a report on Sunday, August 11th. BidaskClub downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 9th. Svb Leerink reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Tuesday, August 13th. Finally, Zacks Investment Research raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, November 19th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Protagonist Therapeutics currently has an average rating of “Buy” and an average price target of $19.60.
The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.68 and a current ratio of 4.68. The stock has a market capitalization of $236.70 million, a price-to-earnings ratio of -4.79 and a beta of 1.52. The company has a 50-day moving average of $10.82 and a 200-day moving average of $11.79.
Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.10. The firm had revenue of $4.14 million for the quarter, compared to analyst estimates of $5.75 million. Protagonist Therapeutics had a negative return on equity of 74.86% and a negative net margin of 209.02%. As a group, analysts expect that Protagonist Therapeutics Inc will post -2.99 earnings per share for the current year.
In related news, EVP Suneel Gupta acquired 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $5.13 per share, for a total transaction of $153,900.00. Following the transaction, the executive vice president now owns 389,824 shares in the company, valued at approximately $1,999,797.12. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bryan Giraudo acquired 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $5.70 per share, with a total value of $45,600.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $57,000. The disclosure for this purchase can be found here. Over the last three months, insiders bought 39,175 shares of company stock valued at $205,493. Insiders own 14.20% of the company’s stock.
Several large investors have recently bought and sold shares of PTGX. Wells Fargo & Company MN lifted its stake in shares of Protagonist Therapeutics by 25.9% during the second quarter. Wells Fargo & Company MN now owns 20,553 shares of the company’s stock valued at $248,000 after buying an additional 4,224 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Protagonist Therapeutics by 99.1% during the second quarter. JPMorgan Chase & Co. now owns 558,729 shares of the company’s stock valued at $6,693,000 after acquiring an additional 278,066 shares in the last quarter. Allianz Asset Management GmbH increased its position in shares of Protagonist Therapeutics by 61.3% during the second quarter. Allianz Asset Management GmbH now owns 124,090 shares of the company’s stock worth $1,503,000 after acquiring an additional 47,175 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Protagonist Therapeutics during the second quarter worth about $442,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Protagonist Therapeutics by 65.1% in the second quarter. Bank of New York Mellon Corp now owns 104,088 shares of the company’s stock worth $1,261,000 after acquiring an additional 41,052 shares in the last quarter. 69.62% of the stock is owned by institutional investors and hedge funds.
Protagonist Therapeutics Company Profile (NASDAQ:PTGX)
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.
See Also: When can a hold rating present a buying opportunity?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.